Accelerating Innovation at Leica Biosystems

Portfolio Evolution: Power of Our Portfolio UNITED BY A COMMON BUSINESS MODEL • Steady consumables stream off extensive installed base High value, 'mission-critical' applications LEADING POSITIONS IN ATTRACTIVE, FAST-GROWING END MARKETS • Long-term, strong secular growth drivers Regulatory requirements DIVERSE & Molecular Dx RAZOR/RAZOR-BLADE SPEC'D IN SERVICE -75% RECURRING STRATEGIC END-MARKET EXPOSURE Clinical Dx Today Applied Biopharma Research/ Industrial Acad. All financial metrics reflect FY 2021E results from continuing operations. Pie charts are a % of total revenue. High-quality businesses in attractive end markets DANAHER

View entire presentation